420135-49-5

Upstream product

• 3588-56-5 N-[(phenylmethoxy)carbonyl]-D-aspartic acid,1,1-dimethylethyl ester 
• 1016258-20-0 (RS)-4-hydroxy-2-{[(phenylmethoxy)carbonyl]amino}butanoic acid 1,1-dimethylethyl ester 

Downstream Products

• 249541-06-8 3-Benzyloxycarbonylamino-4,4-diethoxy-butyric acid tert-butyl ester 
• 420135-50-8 tert-butyl-3-[(benzyloxy)carbonyl]amino-4-pentenoate 
• 147395-39-9 Ac-Tyr-Val-Ala-(RS)-Asp(O^tBu)-H dimethyl acetal 
• 183439-49-8 (RS)-4,4-dimethoxy-3-{[(phenylmethoxy)carbonyl]amino}butanoic acid 1,1-dimethylethyl ester 

Relevant academic research and scientific papers

Diastereoselective synthesis of cyclic β2,3-amino acids utilizing 4-substituted-1,3-oxazinan-6-ones

The 4-substituted-1,3-oxazinan-6-one scaffold is a versatile synthon enabling access to a diverse array of β-amino acid derivatives. In this study, the synthetic utility of the 1,3-oxazinan-6-one is expanded to include the diastereoselective synthesis of

CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS

Cyclic constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R', Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti hypertensive, cardiovascular, renal or endocrine effects are desired.

Linear Natriuretic Peptide Constructs

Linear constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues and at least one amino acid surrogate of formula I: where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group covalently bound to a reactive group of at least one of the amino acid residues or surrogates, pharmaceutical compositions including such linear constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.

C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases

This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients su

Synthesis and evaluation of enantiomeric purity of protected α-amino and peptide aldehydes

The synthesis of enantiomerically pure Ac-Tyr-Val-Ala-Asp(O'Bu)-H dimethyl acetal ((S)-1) is reported, a protected tetrapeptide C-terminal aldehyde belonging to a class of potent, reversible inhibitors of cysteine proteases (e.g., interleukin-1β-convertin